Disease-modifying therapeutics in the Ξ±-synucleinopathies multiple system atrophy (MSA) and Parkinsonβs Disease (PD) are in early phases of clinical testing. Involving patients' preferences including therapy-associated risk willingness in initial stages of therapy development has been increasingly pursued in regulatory approval processes. In our study with 49 MSA and 38 PD patients, therapy-associated risk willingness was quantified using validated standard gamble scenarios for β¦